All articles by GlobalData Healthcare

  1. FDA accelerated review denial is a blow to Spectrum’s poziotinib

    On December 19, Spectrum Pharmaceuticals’ shares tumbled 31% following the FDA decision to decline the company’s request of a breakthrough…
    Read More…

    7 Jan
  2. Chinese biotech hits new heights with approval of first domestic checkpoint inhibitor

    On December 17, China’s National Medical Products Authority (NMPA) conditionally approved the listing of the first locally developed programmed cell…
    Read More…

    4 Jan
  3. New insights into epicutaneous immunotherapy for peanut allergy

    In GlobalData’s analysis of the emerging peanut allergy market titled Peanut Allergy: Opportunity Analysis and Forecasts to 2027, target age…
    Read More…

    21 Dec
  4. Starting young: Aimmune begins new trial treating peanut allergy in toddlers

    On December 19 Aimmune Therapeutics announced the initiation of its Phase III POSEIDON trial exploring the use of the oral…
    Read More…

    21 Dec
  5. Tremfya vs. Cosentyx: Will IL-23s surpass IL-17s in the psoriasis market?

    Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson’s (J&J) interleukin 23 (IL-23) inhibitor Tremfya (guselkumab) in…
    Read More…

    21 Dec
  6. New Phase I data for ASN002 shows promise

    At the Inflammatory Skin Disease Summit (ISDS) in Vienna, Austria, this December, Asana BioSciences presented the first data on the…
    Read More…

    20 Dec
  7. Roche’s Tecentriq triplet versus Keytruda + chemotherapy: an Uphill Struggle?

    On December 7 Roche announced the FDA approval of its triplet of programmed death-ligand 1 (PD-L1) inhibitor Tecentriq (atezolizumab) +…
    Read More…

    17 Dec
  8. Will the UK relax its current regulations for cannabis-based products?

    Recently medicinal cannabis has been at the forefront of media attention in the UK, and in July 2018 the UK…
    Read More…

    18 Sep
  9. Could Bristol-Myers Squibb change the psoriasis market?

    The psoriasis drug market is  fiercely competitive, and strongly held by large pharmaceutical companies that offer biological treatments. These treatments…
    Read More…

    14 Sep
  10. CAR-T toxicity rating system to be finalized by ASBMT by year-end

    The American Society of Blood and Marrow Transplantation (ASBMT) is in the process of developing a toxicity rating system for…
    Read More…

    11 Sep

Go Top